Efficacy of treatment of MS with IFNβ2-1b or glatiramer acetate by monthly brain MRI in the BECOME study

Neurology

Volumn 72, Issue 23, 2009, Pages 1976-1983

  Cadavid, D ^a,b,c   Wolansky, L J ^a,d   Skurnick, J ^a   Lincoln, J ^a   Cheriyan, J ^a   Szczepanowski, K ^a   Kamin, S S ^a,b   Pachner, A R ^a   Halper, J ^b   Cook, S D ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Holy Name Hospital   (United States)

^c BIOGEN   (United States)

^d RadPharm Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; FLUID ATTENUATED INVERSION RECOVERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 67649476210     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000345970.73354.17     Document Type: Article

References (36)

1. Nesbit GM, Forbes GS, Scheithauer BW, Okazaki H, Rodriguez M. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991;180:467-474.
2. Maarouf M, Kuchta J, Miletic H, et al. Acute demyelination: diagnostic difficulties and the need for brain biopsy. Acta Neurochir (Wien) 2003;145:961-969.
3. Wolansky LJ, Finden SG, Chang R, et al. Gadoteridol in multiple sclerosis patients: a comparison of single and triple dose with immediate vs delayed imaging. Clin Imaging 1998;22:385-392.
4. Wolansky LJ, Bardini JA, Cook SD, Zimmer AE, Sheffet A, Lee HJ. Triple-dose versus single-dose gadoteridol in multiple sclerosis patients. J Neuroimaging 1994;4:141-145.
5. Filippi M, Campi A, Martinelli V, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59:540-544.
6. Filippi M, Yousry T, Campi A, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996;46:379-384.
7. Nobauer-Huhmann IM, Ba-Ssalamah A, Mlynarik V, et al. Magnetic resonance imaging contrast enhancement of brain tumors at 3 tesla versus 1.5 tesla. Invest Radiol 2002; 37:114-119.
8. Wolansky LJ, Haghighi MH, Sevdalis E, et al. Safety of serial monthly administration of triple- dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial. J Neuroimaging 2005;15:289-290.
9. Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, Oldstone MB. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34:1368-1372.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
11. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebocontrolled study of interferon-beta1a in relapsing-remitting multiple sclerosis: Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999;46:197-206.
12. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebocontrolled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis: European/ Canadian Glatiramer Acetate Study Group Ann Neurol 2001;49:290-297.
13. van Elteren P. On the combination of independent two- sample tests of Wilcoxon. Bull Int Stat Inst 1960;37:351-361.
14. Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet 2008;371:281-283.
15. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43: 79-87.
16. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359:1453-1460.
17. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59: 1496-1506.
18. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial: The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-661.
19. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial: The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45:1277-1285.
20. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276.
21. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619.
22. Brex PA, Molyneux PD, Smiddy P, et al. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001;57:2185-2190.
23. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis: European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290-297.
24. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002; 58:S3-S9.
25. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002;59:802-808.
26. Barkhof F, Tas MW, Frequin ST, et al. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994;36:382-387.
27. Giovannoni G, Lai M, Thorpe J, et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997;48:1557-1565.
28. Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001;56:1505-1513.
29. Zhao Y, Traboulsee A, Petkau AJ, Li D. Regression of new gadolinium enhancing lesion activity in relapsingremitting multiple sclerosis. Neurology 2008;70:1092- 1097.
30. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766.
31. Tortorella C, Codella M, Rocca MA, et al. Disease activity in multiple sclerosis studied by weekly triple-dose magnetic resonance imaging. J Neurol 1999;246:689-692.
32. Kermode AG, Tofts PS, Thompson AJ, et al. Heterogeneity of blood- brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990;40:229-235.
33. Care B-SH. BEYOND primary outcome: press release. 2007. www.investor.bayer.de/user-upload/2816-. Accessed on February 26, 2009.
34. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-914.
35. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 2001;7:349-353.
36. Flechter S, Vardi J, Pollak L, Rabey JM. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. J Neurol Sci 2002;197:51-55.